Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines

Cancer Chemotherapy and Pharmacology

Volumn 66, Issue 3, 2010, Pages 547-558

  Nannizzi, Sara ^a   Veal, Gareth J ^b   Giovannetti, Elisa ^a,c   Mey, Valentina ^a   Ricciardi, Simona ^a   Ottley, Christopher J ^d   Del Tacca, Mario ^a   Danesi, Romano ^a  

^a UNIVERSITY OF PISA   (Italy)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d DURHAM UNIVERSITY   (United Kingdom)

Author keywords

Colon cancer; DNA adducts; DNA repair; Gene expression; Oxaliplatin; Pemetrexed

Indexed keywords

DIHYDROFOLATE REDUCTASE; FOLYLPOLYGLUTAMATE SYNTHASE; OXALIPLATIN; PEMETREXED; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; PROTEIN KINASE B; THYMIDYLATE SYNTHASE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; GLUTAMIC ACID DERIVATIVE; GUANINE; PLATINUM COMPLEX;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL POPULATION; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA ADDUCT; DNA REPAIR; DOWN REGULATION; DRUG POTENTIATION; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; CELL CYCLE; COLON TUMOR; DOSE RESPONSE; DRUG EFFECT; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTAMATES; GUANINE; HUMANS; MICROSCOPY, FLUORESCENCE; ORGANOPLATINUM COMPOUNDS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 77954680053     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1195-2     Document Type: Article

References (45)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225-249
2. Goldberg RM (2005) Advances in the treatment of metastatic colorectal cancer. Oncologist 10:40-48
3. Meyerhardt JA, Mayer RJ (2005) Systemic therapy for colorectal cancer. N Engl J Med 352:476-487
4. Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E (2002) Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 1:227-235
5. Kweekel DM, Gelderblom H, Guchelaar HJ (2005) Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev 31:90-105
6. Reardon JT, Vaisman A, Chaney SG, Sancar A (1999) Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro- cyclohexylamine-platinum (IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res 59:3968-3971
7. Arnould S, Hennebelle I, Canal P, Bugat R, Guichard S (2003) Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines. Eur J Cancer 39:112-119
8. Chang IY, Kim MH, Kim HB, Lee DY, Kim SH, Kim HY, You HJ (2005) Small interfering RNA-induced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin. Biochem Biophys Res Commun 327:225-233
9. Shirota Y, Stoehlmacher J, Brabender J, Xiong YP, Uetake H, Danenberg KD, Groshen S, Tsao-Wei DD, Danenberg PV, Lenz HJ (2001) ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 19:4298-4304
10. Xu Z, Chen ZP, Malapetsa A, Alaoui-Jamali M, Bergeron J, Monks A, Myers TG, Mohr G, Sausville EA, Scudiero DA, Aloyz R, Panasci LC (2002) DNA repair protein levels vis-a-vis anticancer drug resistance in the human tumor cell lines of the National Cancer Institute drug screening program. Anticancer Drugs 13:511-519
11. Peters GJ, Backus HH, Freemantle S, van Triest B, Codacci-Pisanelli G, van der Wilt CL, Smid K, Lunec J, Calvert AH, Marsh S, McLeod HL, Bloemena E, Meijer S, Jansen G, van Groeningen CJ, Pinedo HM (2002) Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta 1587:194-205
12. Adjei AA (1999) A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer. Br J Clin Pharmacol 48:265-277
13. Bocci G, Danesi R, Allegrini G, Innocenti F, Di Paolo A, Falcone A, Conte PF, Del Tacca M (2002) Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5, 6-dihydrouracil: a case report. Eur J Clin Pharmacol 58:593-595
14. Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL, Shackelford KA, Mendelsohn LG, Soose DJ, Patel VF, Andis SL, Bewley JR, Rayl EA, Moroson BA, Beardsley GP, Kohler W, Ratnam M, Schultz RM (1997) LY231514, a pyrrolo[2, 3-d]pyrimidine-based antifolate that inhibits multiple folaterequiring enzymes. Cancer Res 57:1116-1123
15. Chattopadhyay S, Moran RG, Goldman ID (2007) Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther 6:404-417
16. Giovannetti E, Mey V, Danesi R, Mosca I, Del Tacca M (2004) Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines. Clin Cancer Res 10:2936-2943
17. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543-3551
18. Atkins JN, Jacobs SA, Wieand HS, Smith RE, John WJ, Colangelo LH, Vogel VG, Kuebler JP, Cescon TP, Miller BJ, Geyer CE Jr, Wolmark N (2005) Pemetrexed/oxaliplatin for first-line treatment of patients with advanced colorectal cancer: a phase II trial of the National Surgical Adjuvant Breast and Bowel Project Foundation Research Program. Clin Colorectal Cancer 5:181-187
19. Giovannetti E, Lemos C, Tekle C, Smid K, Nannizzi S, Rodriguez JA, Ricciardi S, Danesi R, Giaccone G, Peters GJ (2008) Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells. Mol Pharmacol 73:1290-1300
20. Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Marini L, Del Tacca M, Danesi R (2005) Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 68:110-118
21. Cooper B, Veal GJ, Radivoyevitch T, Tilby MJ, Meyerson HJ, Lazarus HM, Koc ON, Creger RJ, Pearson G, Nowell G, Gosky D, Ingalls ST, Hoppel CL, Gerson SL (2004) A Phase I and pharmacodynamic study of fludarabine, carboplatin and topotecan in patients with relapsed, refractory, or high-risk acute leukemia. Clin Cancer Res 10:6830-6839
22. Veal GJ, Errington J, Tilby MJ, Pearson A D J, Foot A B M, McDowell H, Ellershaw C, Pizer B, Nowell GM, Pearson DG, Boddy AV (2007) Adaptive dosing and platinum-DNA adduct formation in children receiving high dose carboplatin for the treatment of solid tumours. Br J Cancer 96:725-731
23. Raymond E, Louvet C, Tournigand C, Coudray AM, Faivre S, De Gramont A, Gespach C (2002) Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cells. Int J Oncol 21:361-367
24. Celio L, Sternberg CN, Labianca R, La Torre I, Amoroso V, Barone C, Pinotti G, Cascinu S, Di Costanzo F, Cetto GL, Bajetta E (2009) Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study. Ann Oncol 20:1062-1067
25. Arnould S, Guichard S, Hennebelle I, Cassar G, Bugat R, Canal P (2002) Contribution of apoptosis in the cytotoxicity of the oxaliplatin-irinotecan combination in the HT29 human colon adenocarcinoma cell line. Biochem Pharmacol 64:1215-1226
26. Faivre S, Chan D, Salinas R, Woynarowska B, Woynarowski JM (2003) DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. Biochem Pharmacol 66:225-237
27. Troiani T, Lockerbie O, Morrow M, Ciardiello F, Eckhardt SG (2006) Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases. Mol Cancer Ther 5:1883-1894
28. Temmink OH, Hoebe EK, van der Born K, Ackland SP, Fukushima M, Peters GJ (2007) Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells. Br J Cancer 96:231-240
29. Mey V, Giovannetti E, De Braud F, Nannizzi S, Curigliano G, Verweij F, De Cobelli O, Pece S, Del Tacca M, Danesi R (2006) In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients. Br J Cancer 95:289-297
30. Tonkinson JL, Worzalla JF, Teng CH, Mendelsohn LG (1999) Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma. Cancer Res 59:3671-3676
31. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M (2004) PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30:193-204
32. Nemoto S, Nakamura M, Osawa Y, Kono S, Itoh Y, Okano Y, Murate T, Hara A, Ueda H, Nozawa Y, Banno Y (2009) Sphingosine kinase isoforms regulate oxaliplatin sensitivity of human colon cancer cells through ceramide accumulation and Akt activation. J Biol Chem 284:10422-10432
33. Arango D, Wilson AJ, Shi Q, Corner GA, Aranes MJ, Nicholas C, Lesser M, Mariadason JM, Augenlicht LH (2004) Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br J Cancer 91:1931-1946
34. Hanada M, Feng J, Hemmings BA (2004) Structure, regulation and function of PKB/AKT-a major therapeutic target. Biochim Biophys Acta 1697:3-16
35. Kim JH, Lee KW, Jung Y, Kim TY, Ham HS, Jong HS, Jung KH, Im SA, Kim TY, Kim NK, Bang YJ (2005) Cytotoxic effects of pemetrexed in gastric cancer cells. Cancer Sci 96:365-371
36. Rots MG, Willey JC, Jansen G, Van Zantwijk CH, Noordhuis P, DeMuth JP, Kuiper E, Veerman AJ, Pieters R, Peters GJ (2000) mRNA expression levels of methotrexate resistance-related proteins in childhood leukemia as determined by a standardized competitive template-based RT-PCR method. Leukemia 14:2166-2175
37. Matsumoto S, Igishi T, Hashimoto K, Kodani M, Shigeoka Y, Nakanishi H, Touge H, Kurai J, Makino H, Takeda K, Yasuda K, Hitsuda Y, Shimizu E (2004) Schedule-dependent synergism of vinorelbine and 5-fluorouracil/UFT against non-small cell lung cancer. Int J Oncol 25:1311-1318
38. van der Wilt CL, van Laar JA, Gyergyay F, Smid K, Peters GJ (1992) Biochemical modification of the toxicity and the anti-tumour effect of 5-fluorouracil and cis-platinum by WR-2721 in mice. Eur J Cancer 28 A: 2017-2024
39. Guichard S, Hennebelle I, Bugat R, Canal P (1998) Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line. Biochem Pharmacol 55:667-676
40. Yeh KH, Cheng AL, Wan JP, Lin CS, Liu CC (2004) Down-regulation of thymidylate synthase expression and its steady-state mRNA by oxaliplatin in colon cancer cells. Anticancer Drugs 15:371-376
41. Novakovic P, Stempak JM, Sohn KJ, Kim YI (2006) Effects of folate deficiency on gene expression in the apoptosis and cancer pathways in colon cancer cells. Carcinogenesis 27:916-924
42. Fujishima H, Nakano S, Masumoto N, Esaki T, Tatsumoto T, Kondo T, Niho Y (1997) Inhibition by 5-fluorouracil of ERCC1 and gamma-glutamylcysteine synthetase messenger RNA expression in a cisplatin-resistant HST-1 human squamous carcinoma cell line. Oncol Res 9:167-172
43. Ojima E, Inoue Y, Watanabe H, Hiro J, Toiyama Y, Miki C, Kusunoki M (2006) The optimal schedule for 5-fluorouracil radiosensitization in colon cancer cell lines. Oncol Rep 16:1085-1091
44. Balin-Gauthier D, Delord JP, Pillaire MJ, Rochaix P, Hoffman JS, Bugat R, Cazaux C, Canal P, Allal BC (2008) Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation. Br J Cancer 98:120-128
45. Kopetz S, Lesslie DP, Dallas NA, Park SI, Johnson M, Parikh NU, Kim MP, Abbruzzese JL, Ellis LM, Chandra J, Gallick GE (2009) Synergistic activity of the Src family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Res 69:3842-3849